{"id":"kite-753","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Neurotoxicity"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL3642610","moleculeType":"Small molecule","molecularWeight":"345.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"KITE-753 involves engineering a patient's T cells to express a chimeric antigen receptor (CAR) targeting a defined tumor-associated antigen, enabling the modified T cells to recognize, proliferate, and destroy malignant cells. The CAR construct combines antigen recognition with T cell activation domains to drive potent anti-tumor immunity. This autologous cell therapy is manufactured on a patient-by-patient basis and reinfused to establish durable anti-tumor responses.","oneSentence":"KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:53.174Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell malignancies (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07479797","phase":"PHASE3","title":"Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2026-08","conditions":"Relapsed or Refractory Large B-cell Lymphoma (r/r LBCL)","enrollment":550},{"nctId":"NCT05041309","phase":"","title":"Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells","status":"ENROLLING_BY_INVITATION","sponsor":"Kite, A Gilead Company","startDate":"2021-12-15","conditions":"Solid and Hematological Malignancies","enrollment":1000},{"nctId":"NCT04989803","phase":"PHASE1, PHASE2","title":"Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2021-10-27","conditions":"Relapsed and/or Refractory B-cell Lymphoma","enrollment":247}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KITE-753","genericName":"KITE-753","companyName":"Kite, A Gilead Company","companyId":"kite-a-gilead-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen. Used for Relapsed or refractory B-cell malignancies (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}